Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
4 NC counties are under alert, including Edgecombe County.
Breaking News
Fayetteville police respond to massive fight involving 50 juveniles at Cross Creek Mall
Program
On WRAL at 11: A live report from WRAL's Liz McLaughlin in Paris: How Team USA won their first gold medal today.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novartis Ag ADR
(NY:
NVS
)
110.32
+0.39 (+0.35%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novartis Ag ADR
< Previous
1
2
...
17
18
19
20
21
22
23
24
25
...
28
29
Next >
World Markets News for Wednesday
February 02, 2022
Gold and the Euro are up as the greenback loses traction.
Via
Talk Markets
Why Are Pharming Shares Trading Higher Today?
February 02, 2022
Pharming Group NV (NASDAQ: PHAR) has annou
Via
Benzinga
Novartis Says Sandoz Future Uncertain As Generic Drug Sales Flounder
February 02, 2022
Novartis stock fell Wednesday on a disappointing fourth quarter. The company says it's still reviewing its generic drugs unit.
Via
Investor's Business Daily
The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
February 02, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Recap: Novartis Q4 Earnings
February 02, 2022
Novartis (NYSE:NVS) reported its Q4 earnings results on Wednesday, February 2, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Carlyle, Blackstone Mull $25B Buyout For Novartis' Sandoz Arm: Report
February 01, 2022
Investor groups Blackstone and Carlyle could join forces on a massive $25 billion bid for Novartis AG's unit (NYSE: NVS) Sandoz,
Via
Benzinga
Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues
February 02, 2022
Novartis AG (NYSE: NVS) reported a Q4 net income of $16.31 billion, up from $2.1 billion the previous year,
Via
Benzinga
World Markets News for Tuesday
February 01, 2022
Exxon is splitting into 3 with its new restructuring move: upstream; chemicals; and low-carbon.
Via
Talk Markets
The Last Day In January
January 31, 2022
The market is suspicious of the moves up to right matters.
Via
Talk Markets
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
January 31, 2022
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower.
Via
Benzinga
Earnings Scheduled For February 2, 2022
February 02, 2022
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is likely to report quarterly earnings at $1.57 per share on revenue of $24.59 billion.
Via
Benzinga
Fractional Investment Opportunity In Beachfront Multifamily Property: Last Call To Invest
January 27, 2022
Retail investors have the opportunity to own equity in Eliot on the Ocean, a 94% occupied multifamily mid-rise apartment complex along Revere Beach in Boston’s North Shore...
Via
Benzinga
A New Oral Therapy for Psoriasis Could Be Coming Soon
January 24, 2022
Photo by Towfiqu barbhuiya on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice...
Via
Benzinga
Chopped Stocks
January 18, 2022
The day's theme is sell tech and buy banks.
Via
Talk Markets
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
January 18, 2022
I hope you enjoyed the long weekend, but it's time to get back into investing with the biggest pre-market stock movers for Tuesday!
Via
InvestorPlace
The Daily Biotech Pulse: Bausch Files For Eye Health Unit IPO, LumiraDx Antigen Test Can Detect Omicron, Molecular Partners Discloses Fund Stake
January 14, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Corvus Says Chinese Angel Pharma Starts Phase 1/2 Blood Cancer Study Corvus...
Via
Benzinga
7 Best Long-Term Stocks to Buy and Hold for the Next Decade
January 13, 2022
These seven long-term stocks are among the best picks for truly long-term investors looking for companies to hold for the next decade.
Via
InvestorPlace
Novartis To In-License COVID-19 Treatment From Molecular Partners, After Encouraging Mid-Stage Data
January 10, 2022
After getting positive trial data, Novartis AG (NYSE: NVS) said it would in-license a new drug developing with Molecular Partners AG (NASDAQ: MOLN) to treat...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates
December 31, 2021
Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were...
Via
Benzinga
Markets Inching Up
December 28, 2021
As both China and the SEC are cracking down on Variable Interest Entities raising funds as if they were stocks, these are now in the dumps.
Via
Talk Markets
3 Synthetic Biology Stocks In Focus With Strong Potential
December 26, 2021
Here we discuss three stocks engaged in the field of scientific biology that investors must follow, as they have the potential to generate wealth going forward.
Via
Talk Markets
Week In Review: BeiGene Out-Licenses TIGIT Inhibitor To Novartis In $2.8 Billion Pact
December 26, 2021
Beijing BeiGene out-licensed ex-China rights for its TIGIT inhibitor to Novartis in a multi-faceted $2.8 billion deal. As part of the agreement, BeiGene will have rights to market five Novartis...
Via
Talk Markets
Novartis' Cosentyx Scores FDA Approval For Arthritis In Children, Adolescents
December 23, 2021
The FDA has approved Novartis AG's (NYSE: NVS) Cosentyx (secukinumab) for active enthesitis-related arthritis (ERA) in four years and older, and active juvenile...
Via
Benzinga
FDA Approves Alnylam - Novartis' Leqvio As the First siRNA To Reduce Bad Cholesterol
December 23, 2021
The FDA has approved Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) Leqvio (inclisiran) to lower low-density lipoprotein cholesterol (LDL-C). Leqvio is...
Via
Benzinga
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
December 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug...
Via
Benzinga
A Bit Of Good News
December 22, 2021
US growth figures for Q3 were up from forecasts of 2.1% at 2.3% but well down from the prior quarter level of 6.7%.
Via
Talk Markets
What's Happening With Allarity Therapeutics Stock Today?
December 22, 2021
Allarity Therapeutics Inc (NASDAQ: ALLR) has submitted a marketing application to the FDA seeking approval for dovitinib for the third-line treatment of renal cell...
Via
Benzinga
The Daily Biotech Pulse: Allakos Slips Negative Late-Stage Data, Pfizer & Merck Announce Fresh COVID Pill Deal With UK, Regulatory Setback For Takeda
December 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos's Lirentelimab Flunks Late-Stage Studies In Patients With...
Via
Benzinga
A Peek Into The Markets: US Stock Futures Edge Lower Ahead Of GDP Report
December 22, 2021
Pre-open movers U.S. stock futures traded slightly lower in early pre-market trade after the Dow Jones jumped around 560 points in the previous session. Investors are awaiting...
Via
Benzinga
Novartis Inks Option Agreement For BeiGene Anti-Cancer Therapy For Over $1B
December 20, 2021
BeiGene Ltd (NASDAQ: BGNE) announced an option, collaboration, and license agreement with Novartis AG (NYSE: NVS) to develop, manufacture, and...
Via
Benzinga
< Previous
1
2
...
17
18
19
20
21
22
23
24
25
...
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.